MTMinoko Takanashi

Minoko Takanashi

*This is an algorithmically generated author record based on publicly available information.

Minoko Takanashi has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A NEW CRYOPROTECTANT CONTAINING DIMETHYL SULFOXIDE AND GLUCOSE FOR CORD BLOOD

    by Miyuki Ito, Atsuko Ogawa, Mutsuko Minemoto, Naoko Watanabe-Okochi, Tadashi Nagai, Kazunori Nakajima, Minoko Takanashi

    本邦では1997年に非血縁者間臍帯血移植が実施されてから臍帯血移植数は年々増加し,移植医療における臍帯血の重要性は増している.日本赤十字社関東甲信越さい帯血バンクは臍帯血を凍結保存するため0.8%dextranを含む8%DMSOを使用している.移植時に臍帯血は洗浄しないためDMSOも患者に輸注されるが,DMSOには毒性があるため濃度は低いほうが望ましい.多糖のdextranは輸注時のアナフィラキシーショックの報告もある. 本研究では,dextranに代わり単糖のglucoseをDMSOに混合した新しい凍害保護液5% DMSO-1.5% glucose(5D1.5G)と8% DMSO-1.5% glucose(8D1.5G)について,現行の8% DMSO-0.8% dextran(8D0.8D)との比較検討を行った.5D1.5GはCD34+細胞回収率,CD34+生細胞率において8D0.8Dに比べ有意に高かった.また,有核細胞回収率,CD34陽性細胞数回収率において5D1.5Gが8D1.5Gより有意に高かった.これらの結果から,5D1.5Gは8D0.8Dに変わりうる凍害保護剤と考える.

  • Risk factor analysis of vasovagal reaction from blood donation

    by Minoko Takanashi, Takeshi Odajima, Seiko Aota, Mitsuaki Sudoh, Yoshio Yamaga, Yuriko Ono, Kentaro Yoshinaga, Toshiko Motoji, Koji Matsuzaki, Masahiro Satake, et al.


  • The impact of anti-HLA antibodies on unrelated cord blood transplantations

    by Minoko Takanashi, Yoshiko Atsuta, Koki Fujiwara, Hideki Kodo, Shunro Kai, Hiroyuki Sato, Masatoshi Kohsaki, Hiroshi Azuma, Hidenori Tanaka, Atsuko Ogawa, et al.

    The majority of cord blood transplantations (CBTs) have human leukocyte antigen (HLA) disparities. We investigated the impact that patients' pretransplantation anti-HLA antibodies have on the outcome of CBTs. Testing for anti-HLA antibody and its specificity was performed retrospectively at the Japanese Red Cross Tokyo Blood Center with sensitive solid-phase antibody detection assays. Among 386 CBTs, which were first myeloablative stem cell transplantations for malignancies and used a single unit of cord blood, 89 tested positive. Among the antibody-positive group, the cord blood did not have the corresponding HLA type for the antibody in 69 cases (ab-positive), while 20 cases had specificity against the cord blood HLA (positive-vs-CB). Cumulative incidence of neutrophil recovery 60 days after transplantation was 83% (95% confidence interval [CI], 79%-87%) for the antibody-negative group (ab-negative), 73% (95% CI, 61%-82%) for ab-positive, but only 32% (95% CI, 13%-53%) for the positive-vs-CB (P < .0001, Gray test). With multivariate analysis, the ab-positive showed significantly lower neutrophil recovery than the ab-negative (relative risk [RR] = 0.69, 95% CI, 0.49-0.96, p = .027). The positive-vs-CB had significantly lower neutrophil recovery (RR = 0.23, 95% CI, 0.09-0.56, P = .001) and platelet recovery (RR = 0.31, 95% CI, 0.12-0.81, P = .017) than the ab-negative. Patients' pretransplantation anti-HLA antibodies should be tested and considered in the selection of cord blood.


  • Open Access

    A suggested total size for the cord blood banks of Japan

    by M Takanashi, H Tanaka, M Kohsaki, K Nakajima, K Tadokoro, M Nakabayashi


    • 1 November 2007
      • Vol. 48  (11) , 1462-9

    [The unification of hematopoietic stem cell transplantation registry in Japan and establishment of the TRUMP system].

    by Yoshiko Atsuta, Ritsuro Suzuki, Ayami Yoshimi, Hisashi Gondo, Junji Tanaka, Akira Hiraoka, Koji Kato, Ken Tabuchi, Masahiro Tsuchida, Yasuo Morishima, et al.

    There are four registries of hematopoietic cell transplant in Japan; the Japan Society for Hematopoietic Cell Transplantation (JSHCT), Japanese Society of Pediatric Hematology, Japan Marrow Donor Program and Japan Cord Blood Bank Network, each playing an important role in society by reporting the number and outcomes of transplantations and contributing new findings obtained from studies on individual topics. However, there have been a number of difficulties with analyzing data in overlapping registries and multiple databases at centers affiliated with each of the four registry organizations. JSHCT was pivotal in orchestrating the computerization and unification of hematopoietic stem cell transplant registries for the purpose of resolving these issues and providing a more accurate awareness of hematopoietic stem cell transplantations performed in Japan. JSHCT played a central role in developing the "Transplant Registry Unified Management Program (TRUMP)" to enable transplant institutes to manage patient information with emphasis on convenience to institutes, safety of patient information, and quality of data management. While enhancing domestic registries, the program seeks to coordinate with other hematopoietic cell transplant registries around the world to contribute to the development of registries throughout Asia.


  • Cord Blood Transplantation from Unrelated Donors: A Preliminary Report from the Japanese Cord Blood Bank Network

    by Keiichi Isoyama, Kei Ohnuma, Koji Kato, Tsuneo A. Takahashi, Shunro Kai, Shun-Ichi Kato, Minoko Takanashi, Norihiro Sato, Hiroyuki Sato, Kohichi Kitajima, et al.

    As a source for hematopoietic stem cell transplantation (HSCT), cord blood transplantation from unrelated donors (UCBT) is now considered as an acceptable alternative to patients who need unrelated HSCT. To confirm the findings that mismatched UCBT is feasible, we discussed here the results for 477 patients with hematologic malignancies and non-malignancies who were subjected to UCBT coordinated by the Japanese Cord Blood Bank Network (JCBBN). From February 1997 to October 2001, 411 patients with malignancies and 66 with non-malignancies had UCBT through the cord blood bank in the JCBBN; 311 patients had HLA 0-1 mismatched UCBT; 165, had a 2-4 HLA mismatch. The Kaplan-Meier estimates for 3-year disease-free survival rate (DFS) were 35.2 +/- 2.8% in malignant diseases, and 33.6 +/- 7.2% in patients with non-malignant diseases. The HLA disparity had no effect on DFS, incidence of acute graft-versus-host disease, or engraftment. As reported previously, we also noted the importance of graft cell dose in determining survival in UCBT. Major advantages of UCBT include its rapid availability compared with unrelated donor bone marrow, and tolerance of an HLA mismatch at 2 loci, which will enable extension of the donor pool. This review outlines the latest UCBT progress, with emphasis on practical considerations in HLA-mismatched umbilical cord blood selection.


  • Open Access

    Anti-IgA antibodies detected in patients with nonhemolytic transfusion reactions.

    by Eiko Shimada, Masako Hirano, Yoshiharu Suzuki, Minoko Takanashi, Kazunori Nakajima, Kenji Tadokoro, Takeo Juji

    We used an enzyme-liked immunosorbent assay (ELISA) using polyclonal IgA purified from pooled plasma as an antigen for the screening of anti-IgA antibodies in sera from patients with nonhemolytic transfusion reactions (NHTRs). Among 154 patients referred to our laboratory from April 1994 to January 1995, two were positive for anti-IgA IgG antibodies. Specificites of the anti-IgA antibodies were examined by immunoblotting. Anti-IgA2m(1) and anti-IgA1 were detected in one case each. Sera from both patients contained normal levels of total IgA. In one case, a 43-year-old woman with chronic myelogenous leukemia showed urticaria followed by wheezing dyspnea and fever one hour after the start of platelet concentrate (PC) transfusion. In the other case, a 45-year-old woman with aplastic anemia complained of itching, urticaria, facial edema and nausea immediately after the start of PC transfusion. No antibodies against HLA, platelet-specific antigens or irregular antibodies against red blood cell antigens were detected in either patients' sera collected before transfusion or in the transfused blood in these cases. These findings suggested that these NHTRs might have been caused by subclass and allotype-specific anti-IgA antibodies. These results show that ELISA and Western blotting are useful in the detection of anti-IgA antibodies responsible for NHTRs.